Sodium Polystyrene Sulfonate

Introduction Overview

Generic Name

sodium polystyrene sulfonate

Brand Name

Kayexalate

Dosage Form

oral powder for suspension, oral solution, rectal enema

Drug Class

cation exchange resins

Pharmacokinetics

Absorption:
Sodium polystyrene sulfonate, the active component of Kayexalate, is a cation exchange resin that is not systemically absorbed from the gastrointestinal tract. After oral or rectal administration, the resin remains within the lumen of the intestines, primarily the colon, without absorption into the bloodstream. This property limits systemic exposure and systemic side effects but requires adequate gastrointestinal motility to facilitate its action. The absence of absorption means that sodium polystyrene sulfonate exerts its therapeutic effects locally within the digestive tract by exchanging sodium ions for potassium ions.

Distribution:
Since sodium polystyrene sulfonate is not absorbed, it does not exhibit systemic distribution or attain measurable plasma concentrations. The resin remains confined to the gastrointestinal tract. Distribution is thus limited to the intestinal lumen, where it interacts directly with luminal potassium ions. This localized action is pivotal for its therapeutic use to reduce serum potassium levels without systemic distribution.

Metabolism:
Sodium polystyrene sulfonate is neither metabolized nor bio-transformed by enzymatic or biochemical pathways in the body because it is not absorbed. The resin’s stable polystyrene sulfonate polymer structure remains intact throughout its passage through the gastrointestinal tract. There are no metabolites of clinical significance formed since it does not enter systemic circulation.

Elimination:
Elimination of sodium polystyrene sulfonate occurs exclusively via feces as the resin is excreted along with the bound potassium ions. The duration of passage through the GI tract can vary depending on individual gastrointestinal motility and conditions such as constipation or bowel obstruction. Renal or hepatic pathways are not involved in the elimination of this drug. Retention in the bowel, particularly in patients with decreased motility, can increase the risk of gastrointestinal adverse effects such as constipation or intestinal necrosis.

Dosage Forms

Available Dosage Forms:
Kayexalate is available as an oral powder for suspension, an oral liquid solution, and a rectal enema. The oral powder can be mixed with water, honey, or jam to improve palatability and should not be mixed with potassium-containing liquids such as orange juice. The rectal enema is typically administered by healthcare professionals and followed by a cleansing enema.

Dosages for Adults and Adolescents:
The typical adult dosage varies based on the severity of hyperkalemia and clinical judgment. Oral dosing usually ranges from 15 to 60 grams once to multiple times daily. For severe hyperkalemia, higher doses can be necessary. Rectal doses can be in the range of 30 to 100 grams administered as an enema, often retained for several hours. Treatment duration is individualized and guided by frequent monitoring of serum potassium levels.

Specific Patient Populations:
Kayexalate should be used cautiously or avoided in neonates and infants due to limited safety data and risk of intestinal necrosis. It is contraindicated in patients with bowel obstruction or hypokalemia. Caution is required in patients with impaired gastrointestinal motility, such as those with recent bowel surgery or on medications that slow GI transit. In patients with renal impairment, including those on dialysis, dosing requires close monitoring of electrolyte balance.

Specific Dosage Forms and Strengths:
- Oral powder for suspension: available in varying grams per packet (commonly 15g per packet), mixed with water or other food substances for oral administration
- Oral liquid solution: concentration may vary depending on manufacturer, commonly available as 15g/30mL solutions
- Rectal enema: supplied in kits typically containing 30g to 100g of sodium polystyrene sulfonate in a suspending vehicle; administered by healthcare professional with retention for several hours

Mechanism Of Action

Sodium polystyrene sulfonate functions as a cation exchange resin. Its molecular mechanism relies on its highly sulfonated polystyrene polymer matrix capable of binding to cations. In the gastrointestinal tract, sodium ions on the resin are exchanged for potassium ions present in the intestinal lumen. This selective ion-exchange process facilitates removal of excess potassium from the body via fecal excretion.

At a cellular level within the colon, the resin passes through the lumen without absorption and interacts directly with potassium ions that have been secreted into the intestinal tract from serum through normal physiological processes involving intestinal epithelial cells. By binding potassium, the resin prevents its reabsorption, thereby creating a diffusion gradient favoring potassium movement from blood into the gut lumen.

Biochemically, the high density of sulfonate groups on the polymer provides multiple ionic sites for strong and selective binding of positively charged potassium ions. This ion-exchange is electrostatically driven and reversible, but the resin remains in the gut and the potassium-bound resin is eliminated with feces. This mechanism reduces systemic potassium levels, an effect critical in managing hyperkalemia and preventing cardiac arrhythmias associated with elevated serum potassium.

Clinically, sodium polystyrene sulfonate offers an advantage by not being absorbed systemically, thus limiting toxicity but requiring intact and functional gastrointestinal anatomy and motility. Compared to newer potassium-binding agents which may have different exchange sites or mechanisms (such as sodium zirconium cyclosilicate), Kayexalate is less selective and has a slower onset of action. Research continues to evaluate comparative efficacy and safety profiles, especially concerning risks of intestinal necrosis and excipient-related adverse events.

Pharmacological Actions

Acts as a cation exchange resin that binds potassium ions in the gastrointestinal tract
Decreases serum potassium by promoting fecal excretion of bound potassium
Exchanges sodium ions for potassium ions within the colon lumen
Remains non-absorbed, exerting local action in the intestines
Helps correct hyperkalemia by reducing systemic potassium levels
Does not interfere with potassium delivery to cells but reduces extracellular potassium
May influence electrolyte balance by concomitantly affecting calcium and magnesium levels
Acts slowly, with onset of potassium lowering typically within hours to days
Used primarily in the management of acute and chronic hyperkalemia
Can be administered orally or rectally depending on clinical condition
Effects dependent on intact gastrointestinal motility and absence of obstruction
May interact with other oral medications by binding them and reducing their absorption
Facilitates removal of potassium without relying on renal excretion mechanisms
Can be used adjunctively with other hyperkalemia treatments such as insulin and beta-agonists
Not metabolized or systemically active, minimizing systemic side effects

Therapeutic Or Clinical Uses

Treatment of hyperkalemia (elevated blood potassium levels)
Management of acute or chronic hyperkalemia in patients with renal impairment
Adjunct therapy in dialysis patients to reduce potassium accumulation
Used when rapid lowering of potassium is not critical or as part of combination therapy
Treatment option in hyperkalemia secondary to medications or metabolic conditions
Prevention of life-threatening cardiac arrhythmias in hyperkalemic patients
Alternative to newer potassium binders when cost or availability is a concern
Used in hospital and outpatient settings for potassium regulation
Treatment of hyperkalemia in patients contraindicated for potassium-wasting diuretics
Supportive treatment for electrolyte imbalances involving potassium
May be prescribed in emergency hyperkalemia management where other therapies are insufficient
Part of multimodal management including diet, dialysis, and medication adjustments
Utilized in patients unable to tolerate intravenous therapies for hyperkalemia
Applicable in patients with hyperkalemia due to tissue breakdown or metabolic acidosis
Sometimes used off-label for hyperkalemia prevention in chronic kidney disease

Side Or Adverse Effects

Gastrointestinal disturbance including nausea and vomiting
Diarrhea or constipation, depending on individual response
Abdominal pain or cramping, potentially severe
Risk of intestinal necrosis and ulceration, especially with rectal use
Electrolyte imbalances such as hypokalemia (low potassium levels)
Hypocalcemia (low calcium levels) manifesting as muscle spasms or tingling
Potential for ileus or bowel obstruction exacerbation
Signs of gastrointestinal bleeding such as bloody or tarry stools
Rare allergic reactions including hives, facial/swelling, or respiratory difficulty
Confusion or mental status changes due to electrolyte disturbances
Muscle weakness or cramps related to hypokalemia
Increased thirst or urination due to electrolyte changes
Fever and chills may indicate secondary infection or adverse reaction
Risk of aspiration and airway irritation when inhaling powder during preparation
Loss of appetite during prolonged treatment courses

Precautions

Avoid use in patients with hypokalemia or low serum potassium levels
Contraindicated in known bowel obstruction or significant gastrointestinal motility disorders
Use with caution in patients with severe constipation or bowel disease
Not recommended for oral administration in neonates or infants
Avoid co-administration with potassium-containing liquids or supplements
Separate dosing timing of Kayexalate and other oral medications by at least 3 hours (6 hours if delayed motility)
Monitor electrolyte levels frequently to prevent electrolyte imbalances
Caution in patients with fluid retention or congestive heart failure due to sodium load
Use carefully in patients with history of bowel surgery or disorders
Avoid use with sorbitol-containing preparations due to risk of intestinal necrosis
Ensure patient hydration to support gastrointestinal transit
Inform patients about symptoms of serious gastrointestinal side effects for early recognition
Adjust dosage in renal impairment under medical supervision
Avoid use with antacids or laxatives without medical advice
Use in pregnancy and breastfeeding only if clearly needed and under physician guidance

Warnings

Do not administer orally to newborns due to risk of severe adverse effects
Avoid use in patients with bowel obstruction or suspected intestinal motility impairment
Risk of fatal intestinal necrosis especially when used with sorbitol
Monitor for signs of hypokalemia to avoid cardiac arrhythmias
Discontinue treatment and seek medical care if severe abdominal symptoms develop
Avoid concomitant use with potassium supplements or salt substitutes without medical approval
Potential for serious electrolyte disturbances requiring frequent laboratory monitoring
Avoid administration in patients with known allergies to the drug or its components
Maintain separation of dosing with other oral medicines to reduce drug interactions
Use caution in patients with compromised immune systems or concurrent infections
Store at room temperature away from moisture and heat to preserve drug stability
Avoid aspiration or inhalation of powder during preparation to prevent respiratory irritation
Patients should not share medication to prevent dosing errors or contamination
Ensure secure storage out of reach of children to prevent accidental ingestion
Report any signs of gastrointestinal bleeding immediately to health care providers

Contraindication

Hypokalemia (low potassium levels) as Kayexalate can exacerbate potassium depletion
Bowel obstruction or ileus due to risk of worsening obstruction and necrosis
Newborns and infants, particularly for oral administration, due to safety concerns
Known hypersensitivity or allergy to sodium polystyrene sulfonate or resin components
Use with sorbitol-containing products due to increased risk of intestinal necrosis
Patients with severe constipation or impaired gastrointestinal motility without medical supervision
Concurrent use with potassium-containing oral medications or supplements unless directed
Pregnancy or breastfeeding only when benefits outweigh potential risks and under medical advice
Severe dehydration or fluid imbalance states prior to correction
Patients who cannot hold or retain rectal dose enemas safely
Known sensitivity to cation exchange resins or sulfonate derivatives
History of intestinal ischemia or inflammatory bowel disease
Concomitant use with certain immunosuppressive medications without close monitoring
Severe electrolyte imbalance other than hyperkalemia without stabilization
Patients unable to tolerate oral or rectal administration routes

Drug Interactions

May reduce absorption of concurrent oral medications by binding them in the gut
Avoid taking other oral medications within 3 hours before or after Kayexalate administration
In conditions of slow gastrointestinal transit, separation should be extended to 6 hours
Possible interaction with digoxin leading to altered therapeutic levels
Lithium absorption can be impaired when co-administered
May decrease thyroid hormone absorption, including thyroxine
Immunosuppressive drugs such as steroids or anti-cancer agents may have altered bioavailability
Avoid concomitant use with potassium supplements or salt substitutes
Antacids and laxatives may reduce Kayexalate effectiveness or increase adverse effects
Concurrent use with drugs affecting gastrointestinal motility may alter efficacy
May affect blood levels of other cations like calcium and magnesium when given concurrently
Potential interference with absorption of vitamins and herbal supplements taken orally
Drug interaction risk necessitates close monitoring and dose adjustment of affected medications
No systemic pharmacokinetic interactions due to lack of absorption, but local GI interactions are significant
Clinicians should review all medications and adjust administration schedules accordingly

Preparations Of The Drug

Kayexalate oral powder for suspension: packets containing typically 15 grams of sodium polystyrene sulfonate to be mixed with water or palatable solutions
Kayexalate oral liquid suspension available in various concentrations (e.g., 15g/30mL), ready for oral administration
Rectal enema preparations: suspensions containing 30g to 100g sodium polystyrene sulfonate intended for retention enema administration
Powder formulations designed for mixing immediately prior to administration to maintain efficacy
Packaged as single-dose packets to ensure accurate dosing and reduce contamination risk
Formulations require avoidance of mixing with potassium-containing solutions to prevent loss of efficacy
Enema formulations accompanied by cleansing enemas for improved potassium removal
Sterile or non-sterile formulations depending on route of administration and manufacturer specifications
Available in kits for hospital or outpatient use, including measuring devices or administration supplies
No FDA-approved brand Kayexalate available currently in U.S.; generic sodium polystyrene sulfonate products are used as alternatives
Storage recommendations: store at room temperature, protected from moisture and heat to preserve drug stability
Powder formulations come with detailed instructions for reconstitution and administration
Not to be administered orally to neonates due to preparation and safety considerations
Clinical guidelines recommend close adherence to preparation techniques to avoid adverse events
Labeling includes warnings about potential severe GI adverse effects and instructions for emergency contact